Home›US Markets›Sectors›New pancreatic cancer drug price reflects decades of c…

New pancreatic cancer drug price reflects decades of cancer drug inflation

A new pancreatic cancer therapy, Rasonque from Revolution Medicines, is priced at $480,000 per year, highlighting how cancer drug costs have risen over two decades.

Reported · Written up by our desk · Sectors

The New York Times Business reports that Revolution Medicines is pricing Rasonque, a new pancreatic cancer treatment, at $480,000 per year.

The outlet frames the drug’s price as evidence of a “new normal” for cancer medicines, noting that cancer drug prices have become far more expensive over the past two decades.

More like this

Sources